Elan’s trouble with dates
Elan president Carlos Paya entered the JP Morgan Healthcare Conference hoping to put behind him the controversy over statements attributed to him over a possible extension to the duration of Phase III trials for the company’s Alzheimer’s drug bapineuzimab currently slated to last 18 months. Unfortunately, as he moved to clarify -referring to recent confusion – he again alluded to 24 months before hastily correcting himself.
